Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Inclusion criteria

INCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL OR ALL (COHORT A) * CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody, or who have failed tyrosine kinase or phosphatidylinositol 3 (PI3) kinase inhibitors, or who were not eligible for or declined such therapy; patients with fludarabine refractory disease are eligible * Mantle cell lymphoma patients who are beyond first remission and previously treated with chemoimmunotherapy; patients who have relapsed following autologous hematopoietic cell transplant (HCT) are eligible * ALL patients who have relapsed or have residual disease following treatment with curative intent; ALL patients must have ROR1 expressed on \> 90% of the leukemia blasts to be eligible * Confirmation of diagnosis by internal pathology review of initial or subsequent biopsy or other pathologic material at the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA) * Evidence of ROR1 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen * Karnofsky performance status \>= 70% * Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year * Fertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion * Ability to understand and provide informed consent INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): * Patients with non-small cell lung cancer that is metastatic or inoperable and who have been treated with at least one line of prior therapy or declined conventional therapy * Patients with known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations must have been treated on at least one line of molecularly targeted therapy (e.g., erlotinib, crizotinib) * Patients must have measurable disease by at least one of the criteria below: * Extra skeletal disease that can be accurately measured in at least one dimension as \>= 10 mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Skeletal or bone-only disease measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging * ROR1 expression in \> 20% of the primary tumor or metastasis by immunohistochemistry (IHC) * Karnofsky performance status of \>= 70% * Patients must be off chemotherapy for a minimum of 3 weeks prior to start of treatment; targeted therapies must be stopped at least 3 days prior to start of lymphodepletion * Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year * Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion * Ability to understand and provide informed consent INCLUSION CRITERIA FOR TNBC: * Histologically confirmed diagnosis of metastatic TNBC; i.e. breast cancer that is estrogen receptor (ER) negative (=\< 10%), progesterone receptor (PR) negative (=\< 10%), and human epidermal growth factor receptor 2 (HER2) negative (0 or 1+ by immunohistochemistry or negative for gene amplification by fluorescence in situ hybridization \[FISH\]) * Patients must have measurable disease by at least one of the criteria below: * Extra skeletal disease that can be accurately measured in at least one dimension as \>= 10 mm with conventional CT techniques as defined by RECIST 1.1 * Skeletal or bone-only disease measurable by FDG PET imaging * Patients must have received standard adjuvant, neoadjuvant, and/or metastatic chemotherapy per National Comprehensive Cancer Network (NCCN) or institutional practice; no maximum on number of prior systemic treatment regimens * Patients may receive agents to protect against skeletal related complications such as zoledronic acid or denosumab * ROR1 expression in \> 20% of the primary tumor or metastasis by IHC * Karnofsky performance status of \>= 70% * Patients must be off chemotherapy for a minimum of 3 weeks prior to planned leukapheresis * Negative pregnancy test for women of childbearing potential; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year * Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion * Ability to understand and provide informed consent